Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.
Dreyfus
David H
DH
D000328:Adult; D000799:Angioedema / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D001491:Basophils / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D000069444:Omalizumab; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011755:Pyrophosphatases / Q000378:metabolism; D013967:Thyroiditis, Autoimmune / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D013972:Thyrotropin / Q000097:blood; D014581:Urticaria / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; C427944:ENPP3 protein, human; C006606:anti-thyroglobulin; D000069444:Omalizumab; D013972:Thyrotropin; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases